ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Black Men Face Disparate Cancer Burden; Minority Rates Vary, Klausner Tells House

April 3, 1998

DCPC Board Approves Concepts for $28.5 Million Polyp Trial, Other Nutrition Related Studies

May 19, 1989

Cooperative Groups Advised To Plan For Future Of Less Funding from NCI

June 16, 1995

ACS Adopts Principles As Basis For Reform Of Health Care System

July 17, 1992

Samuel Waksal Resigns From ImClone Following Unimpressive ASCO Presentation

May 24, 2002

GAO Report On NCI Cancer Control Contracts (Continued)

August 1, 1980